Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
The trouble-stricken company has sought appointment with at least two major hospitals -- Mumbai-based Jaslok and Gurgaon-based Medanta Medicity.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
Assessment by security forces suggests the Naxals had reached Sukma in small batches from different states to carry out the attack, reports Gyan Varma
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Singh says Japanese pharma giant's allegations false.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Dinesh Thakur says he waved the red flag only after Ranbaxy didn't respond to his concerns.
The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
Data contradict Swiss drug major's claim that India does not respect IPR.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances